journal
MENU ▼
Read by QxMD icon Read
search

Clinical Lymphoma, Myeloma & Leukemia

journal
https://read.qxmd.com/read/30772299/feasibility-of-qualitative-testing-of-bcr-abl-and-jak2-v617f-in-suspected-myeloproliperative-neoplasm-mpn-using-rt-pcr-reversed-dot-blot-hybridization-rt-pcr-rdb
#1
Najmiatul Masykura, Ummu Habibah, Siti Fatimah Selasih, Soegiarto Gani, Cosphiadi Irawan, Sugiyono Somoastro, Ahmad Rusdan Handoyo Utomo
BACKGROUND: Defining the presence of BCR-ABL transcript in suspected myeloproliferative neoplasm is essential in establishing chronic myeloid leukemia. In the absence of BCR-ABL, the conventional diagnostic algorithm recommends JAK2 V617F mutation testing to support diagnosis of other MPN diseases such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis. In certain cases of thrombocythemia, simultaneous upfront testing of both BCR-ABL and JAK2 may be desirable. We wanted to test the feasibility of multiplex detection of BCR-ABL transcript variants and JAK2 V617F mutation simultaneously using the reverse transcriptase polymerase chain reaction (RT-PCR)-based reverse dot-blot hybridization (RDB) method...
January 19, 2019: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/30770307/adding-oral-pioglitazone-to-standard-induction-chemotherapy-of-acute-myeloid-leukemia-a-randomized-clinical-trial
#2
Mojtaba Ghadiany, Mahdi Tabarraee, Sina Salari, Shirin Haghighi, Hamid Rezvani, Seyedeh Najmeh Ghasemi, Hamidreza Karimi-Sari
BACKGROUND: The hypothesis of an effect by thiazolidinedione on leukemia cells was proposed 2 decades ago, but there is little clinical evidence regarding its efficacy. We evaluated the safety and efficacy of adding pioglitazone to standard induction chemotherapy in patients with acute myeloid leukemia (AML). PATIENTS AND METHODS: In this randomized clinical trial, newly diagnosed AML patients were randomized to 1 of 2 groups. Patients in both groups received cytarabine (100 mg/m2 per day for 7 days) and daunorubicin (60 mg/m2 per day for 3 days)...
January 19, 2019: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/30704934/clinicopathological-profile-of-myelomatous-pleural-effusion-single-center-real-world-experience-and-review-of-literature
#3
Uday Yanamandra, Prateek Deo, Kamal Kant Sahu, Ram Vasudevan Nampoothiri, Nalini Gupta, Anusree Prabhakaran, Deb Prasad Dhibhar, Alka Khadwal, Gaurav Prakash, Man Upadesh Singh Sachdeva, Deepesh Lad, Neelam Varma, Subhash Varma, Pankaj Malhotra
BACKGROUND: Multiple myeloma (MM) is a hematologic malignancy of plasma cell origin. MM primarily affects bone marrow, but extramedullary sites can also be involved. Myelomatous pleural effusion (MPE) is an atypical and rare complication of MM. We aimed to systematically study the incidence and clinicopathologic profile of patients with MPE in a real-world setting. PATIENTS AND METHODS: In this retrospective study, 415 consecutive patients with MM managed at a tertiary care center in North India during a study period of January 1, 2010 to December 31, 2015 were evaluated for MPE...
January 3, 2019: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/30704932/lenalidomide-related-progressive-multifocal-leukoencephalopathy-a-case-report-and-review-of-drug-related-cases-in-multiple-myeloma
#4
Stephanie Anderson, Matthew Kiernan, P Joy Ho
No abstract text is available yet for this article.
January 3, 2019: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/30686775/emerging-treatment-strategies-for-primary-breast-extranodal-marginal-zone-lymphoma-of-mucosa-associated-lymphoid-tissue
#5
Ethan B Ludmir, Sarah A Milgrom, Chelsea C Pinnix, Jillian R Gunther, Jason Westin, Luis E Fayad, Joseph D Khoury, L Jeffrey Medeiros, Bouthaina S Dabaja, Loretta J Nastoupil
INTRODUCTION: We report our experience in treating patients with primary breast extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) to better elucidate the natural history and optimal treatment approach for these patients. PATIENTS AND METHODS: Patients with localized primary breast MALT lymphoma treated between 1995 and 2016 were included. Disease-related endpoints including progression-free survival (PFS) were analyzed. RESULTS: Eleven patients met inclusion criteria; all patients were women with a median age of 62 years (range, 42-75 years)...
January 3, 2019: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/30686772/assessing-the-effectiveness-of-treatment-sequences-for-older-patients-with-high-risk-follicular-lymphoma-with-a-multistate-model
#6
Çağlar Çağlayan, Hiromi Terawaki, Turgay Ayer, Jordan S Goldstein, Ashish Rai, Qiushi Chen, Christopher Flowers
BACKGROUND: Disease progression within < 2 years of initial chemoimmunotherapy and patient age > 60 years have been associated with poor overall survival (OS) in follicular lymphoma (FL). No standard treatment exists for these high-risk patients, and the effectiveness of sequential therapies remains unclear. PATIENTS AND METHODS: We studied the course of FL with first-, second-, and third-line treatment. Using large population-based data, we identified 5234 patients with FL diagnosed in 2000 to 2009...
January 3, 2019: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/30685184/severe-protein-losing-enteropathy-due-to-an-indolent-splenic-lymphoma-case-report-and-review-of-the-literature
#7
Leonard Naymagon, Stephen Ward, Steven Naymagon, Shyamala Navada
No abstract text is available yet for this article.
January 3, 2019: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/30745139/prognostic-significance-of-serum-copper-in-patients-with-cutaneous-t-cell-lymphoma
#8
Eric C Vonderheid, Andrew R Martinez
BACKGROUND: Serum copper has been reported to be increased in various cancers, including lymphoma. The purpose of the present study was to investigate the clinical and prognostic importance of serum copper levels in patients with cutaneous T-cell lymphoma (CTCL). PATIENTS AND METHODS: Serum copper was measured in 60 men and 38 women with mycosis fungoides (MF) and 14 men and 3 women with erythrodermic CTCL (6 with Sézary syndrome) consecutively evaluated from July 1980 to June 1985...
January 2, 2019: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/30691994/treatment-patterns-and-survival-outcomes-in-patients-with-follicular-lymphoma-a-2007-to-2015-humedica-database-study
#9
Vicki A Morrison, Yaping Shou, Jill A Bell, Laurie Hamilton, Augustina Ogbonnaya, Aditya Raju, Kristin Hennenfent, Michael Eaddy, Aaron Galaznik
BACKGROUND: Few studies have evaluated real-world treatment patterns and survival in follicular lymphoma (FL). This study evaluated these outcomes among newly diagnosed patients with FL in routine clinical care. PATIENTS AND METHODS: A retrospective study was conducted in newly diagnosed patients with FL from Humedica, a large United States electronic medical record database, from January 1, 2008 to July 31, 2015. Patients were followed from treatment initiation until death, loss to follow-up, or end of study (September 30, 2015)...
January 2, 2019: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/30686773/influenza-vaccination-documentation-rates-during-the-first-year-after-diagnosis-of-diffuse-large-b-cell-lymphoma
#10
Andres Chang, Jackelyn B Payne, Pamela B Allen, Jean L Koff, Rafi Ahmed, Christopher R Flowers, Robert A Bednarczyk
INTRODUCTION: Influenza infection causes significant morbidity and mortality in patients with cancer, and annual influenza vaccination for individuals with cancer is recommended. We sought to examine the documentation rate of influenza vaccine administration, refusal, or counseling in the first year after diagnosis of diffuse large B cell lymphoma (DLBCL) for patients across 3 hospitals in 2 health care systems. PATIENTS AND METHODS: Documentation of vaccine administration, refusal, or counseling by physicians, advanced practice providers, or nursing staff during the first period of influenza vaccine availability after diagnosis (August to April) was assessed in medical records of patients diagnosed with DLBCL between February 2015 and October 2017 who presented to Emory St...
January 2, 2019: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/30770308/clinical-benefit-risk-profile-of-lenalidomide-in-patients-with-lower-risk-myelodysplastic-syndromes-without-del-5q-results-of-a-phase-iii-trial
#11
Guillermo Garcia-Manero, Antonio Almeida, Pierre Fenaux, Norbert Gattermann, Aristoteles Giagounidis, Stuart L Goldberg, Keiya Ozawa, Jerry Weaver, Valeria Santini
BACKGROUND: In the phase III MDS-005 study of patients with lower-risk, non-del(5q) myelodysplastic syndromes, lenalidomide was associated with a higher rate of ≥ 8 weeks red blood cell transfusion independence (RBC-TI) compared with placebo, but also with a higher risk of hematologic adverse events (AEs). PATIENTS AND METHODS: This analysis evaluated the ratio of clinical benefit-risk in patients treated with lenalidomide or placebo, and assessed the effect of lenalidomide dose reductions on response...
December 21, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/30665867/impact-of-blood-count-recovery-based-complete-remission-before-allogeneic-hematopoietic-stem-cell-transplantation-on-survival-in-patients-with-acute-myeloid-leukemia
#12
Rafiye Ciftciler, Haluk Demiroglu, Yahya Buyukasık, Salih Aksu, Hakan Goker
BACKGROUND: Patients who achieve complete remission (CR) with incomplete blood count recovery (CRi) in acute myeloid leukemia (AML) have inferior overall survival and lower progression-free survival. The aim of this study was to define whether blood count recovery-based CR before allogeneic hematopoietic stem cell transplantation (alloHSCT) had an impact on survival in patients with AML. MATERIALS AND METHODS: This study has been performed in a retrospective manner...
December 21, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/30723035/addition-of-cyclophosphamide-on-demand-to-lenalidomide-and-corticosteroids-in-patients-with-relapsed-refractory-multiple-myeloma-a-retrospective-review-of-a-single-center-experience
#13
Majed Alahmadi, Esther Masih-Khan, Eshetu G Atenafu, Christine Chen, Vishal Kukreti, Rodger Tiedemann, Suzanne Trudel, Donna E Reece
INTRODUCTION: The combination of lenalidomide and dexamethasone (Len-Dex) is an established regimen for patients with relapsed or refractory myeloma. To prolong the benefit of this effective regimen, the Myeloma Program at Princess Margaret Cancer Centre has routinely added a third agent, oral cyclophosphamide (Cy) given weekly, to Len-Dex at disease progression. PATIENTS AND METHODS: In the present report, we describe the cases of 53 patients who had received Len-Dex-Cy for a minimum of 4 weeks from January 2007 to December 2014 after progression with Len-Dex alone...
December 20, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/30713125/a-phase-ii-study-to-determine-the-safety-and-efficacy-of-the-oral-inhibitor-of-indoleamine-2-3-dioxygenase-ido-enzyme-incb024360-in-patients-with-myelodysplastic-syndromes
#14
Rami S Komrokji, Sheng Wei, Adam W Mailloux, Ling Zhang, Eric Padron, David Sallman, Jeffrey E Lancet, Sara Tinsley, Lisa A Nardelli, Javier Pinilla-Ibarz, Pearlie K Epling-Burnette, Alan F List
BACKGROUND: INCB024360 is an oral inhibitor of the enzyme indoleamine 2,3-dioxygenase (IDO), which catalyzes the degradation of tryptophan to kynurenine. Preclinical data suggest that IDO1 inhibition by INCB024360 will increase T cell proliferation, and decrease T regulatory cells and myeloid derived suppressor cells suppressive activity. We conducted a phase II study to explore activity and pharmacodynamics of INCB024360 in patients with myelodysplastic syndromes. PATIENTS AND METHODS: All patients were treated with INCB024360 600 mg orally twice a day for at least 16 weeks...
December 20, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/30704933/a-frontline-approach-with-peripherally-inserted-versus-centrally-inserted-central-venous-catheters-for-remission-induction-chemotherapy-phase-of-acute-myeloid-leukemia-a-randomized-comparison
#15
Marco Picardi, Roberta Della Pepa, Claudio Cerchione, Novella Pugliese, Chiara Mortaruolo, Fabio Trastulli, Claudia Giordano, Francesco Grimaldi, Irene Zacheo, Marta Raimondo, Federico Chiurazzi, Fabrizio Pane
BACKGROUND: The incidence of peripherally inserted central catheter (PICC)-related adverse events has been uncertain in the setting of acute myeloid leukemia (AML) compared with the incidence of centrally inserted central catheter (CICC) adverse events. PATIENTS AND METHODS: We conducted a monocentric, randomized trial of patients with previously untreated AML. Of the 93 patients, 46 had received a PICC and 47 had received a CICC as frontline intravascular device...
December 20, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/30686774/outcome-of-childhood-acute-megakaryoblastic-leukemia-children-s-cancer-hospital-egypt-57357-experience
#16
Noura Maarouf, Sonia Mahmoud, Reham Khedr, Leslie Lehmann, Khaled Shaaban, Sherine Ibrahim, Sonya Fahmy, Omneya Hassanain, Nouran Nader, Alaa Elhaddad
INTRODUCTION: Acute megakaryoblastic leukemia is a rare subtype of pediatric acute myeloid leukemia (AML) with poor outcomes in patients with non-Down syndrome. The reported outcomes have been poor, and the prognostic factors have not been clearly determined. PATIENTS AND METHODS: To evaluate the prognostic significance of various cytogenetic abnormalities and minimal residual disease status determined by flow cytometry after induction I, we retrospectively analyzed the data of 80 patients with non-Down syndrome with a diagnosis of M7 AML treated at Children's Cancer Hospital Egypt (CCHE-57357) from July 2007 through December 2016...
December 20, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/30685183/prognostic-value-of-1q21-gain-in-multiple-myeloma
#17
Dangui Chen, Di Zhou, Jingyan Xu, Rongfu Zhou, Jian Ouyang, Bing Chen
BACKGROUND: Multiple myeloma (MM) is a heterogeneous disease characterized by chromosomal translocation, deletion, and amplification in plasma cells, resulting in a huge heterogeneity in its outcomes. In the era of novel agents such as bortezomib, thalidomide, and the cycles of treatment, risk stratification by chromosomal aberrations may enable a more rational risk-stratification selection of therapeutic approaches in patients with MM. PATIENTS AND METHODS: We performed a retrospective study in 63 patients with MM; 29 (46...
December 20, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/30679106/hematopoietic-progenitor-cell-mobilization-for-autologous-stem-cell-transplantation-in-multiple-myeloma-in-contemporary-era
#18
REVIEW
Satyam Arora, Navneet S Majhail, Hien Liu
Successful stem cell mobilization and adequate harvesting of hematopoietic progenitor cells (HPCs) is necessary for patients with multiple myeloma (MM) undergoing high-dose chemotherapy and autologous stem cell transplantation (ASCT). Several advances have increased the efficiency and yield of HPC collection methods, and sufficient CD34+ cell collection can be expected for most patients with MM considered to be ASCT candidates. However, in some patients, HPCs will fail to mobilize and an adequate number of CD34+ cells will not be collected...
December 20, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/30660512/cardiovascular-risk-and-cardiovascular-events-in-patients-with-chronic-myeloid-leukemia-treated-with-tyrosine-kinase-inhibitors
#19
Paola Morelato Assunção, Tamires Prates Lana, Márcia Torresan Delamain, Gislaine Oliveira Duarte, Roberto Zulli, Irene Lorand-Metze, Carmino Antonio de Souza, Erich Vinicius de Paula, Katia Borgia Barbosa Pagnano
BACKGROUND: Cardiovascular events (CVEs) have been observed in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors. PATIENTS AND METHODS: We retrospectively evaluated the incidence of CVEs on 233 consecutive patients with chronic myeloid leukemia, of which 116 were treated with imatinib, 75 with dasatinib, and 42 with nilotinib. The median follow-up was 2047, 1712, and 1773 days, respectively. RESULTS: The cumulative incidence of CVEs was 4...
December 20, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/30635233/phase-ii-trial-of-mek-inhibitor-binimetinib-mek162-in-ras-mutant-acute-myeloid-leukemia
#20
Abhishek Maiti, Kiran Naqvi, Tapan M Kadia, Gautam Borthakur, Koichi Takahashi, Prithviraj Bose, Naval G Daver, Ami Patel, Yesid Alvarado, Maro Ohanian, Courtney D DiNardo, Jorge E Cortes, Elias J Jabbour, Guillermo Garcia-Manero, Hagop M Kantarjian, Farhad Ravandi
BACKGROUND: Relapsed and refractory (R/R) acute myeloid leukemia (AML) continues to be a therapeutic challenge with poor outcomes. Dysregulation of the mitogen-activated protein (MAP) kinase/extracellular-signal regulated kinase (ERK) pathway frequently occurs in AML and myelodysplastic syndrome (MDS). Preclinical studies and early-phase trials have shown promise for MAP-ERK kinase (MEK) inhibition in AML. We evaluated the safety and efficacy of the MEK 1/2 inhibitor binimetinib in advanced myeloid malignancies...
December 20, 2018: Clinical Lymphoma, Myeloma & Leukemia
journal
journal
42898
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"